These 2 Coronavirus Vaccine Stocks Could Be Game-Changers
The coronavirus vaccine race is reaching its final stages. Ten programs are in phase 3 trials, and frontrunners Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) say they expect data readouts on their candidates by the end of this month. If they or another player win the first emergency use authorizations (EUA) or approvals, we might say the race is over. But it actually won't be.
Considering the global need for a vaccine, companies that cross the finish line much later could still seize a share of the market. In fact, two players that aren't ahead from a timeline perspective have one particular advantage. Both are developing vaccine candidates that could be game-changers -- and if successful, they could take a big chunk of the market.
Image source: Getty Images.
Source Fool.com
